LCT
Director Trades
| Date | Director | Value |
|---|
Company News
Living Cell Technologies to head pre-clinical studies of AI-116 cannabinoid to treat dementia
Living Cell Technologies (ASX: LCT) has entered into a research agreement with Melbourne’s La Trobe University for a range of pre-clinical studies assessing the effect of cannabinoid-based combination drug AI-116 on patients with dementia. The studies will employ state-of-the-art experimental techniques which are expected to provide valuable insights into AI-116’s mechanism of action by comparing […]
Market wrap: ASX falls as Bank of Japan flexes its muscles
The Australian share market shed 0.7% in Friday trade as the Bank of Japan shook up markets with a pledge to be more flexible in managing interest rates. The 52.3-point fall to 7403.6 points on the ASX 200 was a solid fall but still left the Australian market up 1.2% for the week after it […]
LCT makes headway on drug candidate pipeline for major disease treatments
Melbourne-headquartered biotechnology company Living Cell Technologies (ASX: LCT) made significant strides in its efforts to create a pharmaceutical company with a diversified product candidate pipeline during a busy June quarter. Boosted by a successful entitlement offer, LCT enters the second half of the year with a reported cash balance of $4.1 million at 30 June. […]
Living Cell Technologies files patent application over combination drug to treat dementia
Living Cell Technologies (ASX: LCT) has filed a provisional patent application over combination drug candidate AI-116 which contains cannabidiol (CBD) and an off-patent pharmaceutical ingredient for use in the treatment of dementia. The application establishes the priority date of the invention ahead of potential competitor companies and marks the start of a second research and […]
ASX biotech company LCT eyes artificial intelligence-powered drug discovery and development
Biotechnology company Living Cell Technologies (ASX: LCT) is preparing to take the next step in a major makeover with a proposal to be put to shareholders to change its name to Algorae Pharmaceuticals. The company, which has made several recent significant changes and appointments, also has a pending trademark lodged for the Algorae name. According […]
Living Cell Technologies moves closer to third clinical trial of NTCELL for Parkinson’s disease
Living Cell Technologies (ASX: LCT) has released a market update on its planned NTCELL clinical trial program for Parkinson’s disease. The company has confirmed that contractor NZeno has finalised all agreed aspects of a dedicated pig herd and surgical facility at NZeno’s site in New Zealand. The facilities have been built exclusively for Living Cell […]
Living Cell Technologies appoints new chief scientific officer
Biotechnology company Living Cell Technologies (ASX: LCT) has appointed experienced Australian research scientist Dr James A Mckenna to the role of chief scientific officer. Dr Mckenna holds a doctorate in biochemistry and molecular biology from the University of Melbourne. He has worked as a research scientist for 23 years in the areas of academic science, […]
Living Cell Technologies publishes encouraging follow up data for Parkinson’s drug NTCELL
Biotechnology company Living Cell Technologies (ASX: LCT) has published what could end up proving to be pivotal findings from an 18-month follow up of 18 patients in its existing Phase 2b study of NTCELL, the company’s proposed treatment for Parkinson’s disease. The biotech company is developing NTCELL, an “alginate-coated capsule” containing clusters of neonatal porcine choroid […]
Living Cell Technologies Parkinson’s disease treatment shows signs of efficacy in phase II study
Treating nervous system-related conditions could soon be taking a technology-induced futuristic turn after biotechnology developer Living Cell Technologies (ASX: LCT) confirmed the safety profile of its NTCELL product, a potentially revolutionary method of treating debilitating conditions such as Parkinson’s disease and Alzheimer’s. Following a phase 2b study of NTCELL, LCT says it has received official […]